首页> 外文期刊>Schizophrenia research and treatment >Vascular Endothelial Growth Factor and Brain-Derived Neurotrophic Factor in Quetiapine Treated First-Episode Psychosis
【24h】

Vascular Endothelial Growth Factor and Brain-Derived Neurotrophic Factor in Quetiapine Treated First-Episode Psychosis

机译:喹硫平治疗的初发性精神病患者的血管内皮生长因子和脑源性神经营养因子

获取原文
           

摘要

Objective. It has been suggested that atypical antipsychotics confer their effects via brain-derived neurotrophic factor (BDNF). We investigated the effect of quetiapine on serum levels of BDNF and vascular endothelial growth factor (VEGF) in drug-naive first-episode psychosis subjects.Methods. Fifteen patients drawn from a larger study received quetiapine treatment for twelve weeks. Baseline levels of serum BDNF and VEGF were compared to age- and sex-matched healthy controls and to levels following treatment. Linear regression analyses were performed to determine the relationship of BDNF and VEGF levels with outcome measures at baseline and week 12.Results. The mean serum BDNF level was significantly higher at week 12 compared to baseline and correlated with reductions in Brief Psychiatric Rating Scale (BPRS) and general psychopathology scores. Changes in serum VEGF levels also correlated significantly with a reduction in BPRS scores, a significant improvement in PANNS positive symptoms scores, and displayed a positive relationship with changes in BDNF levels.Conclusions. Our findings suggest that BDNF and VEGF are potential biomarkers for gauging improvement of psychotic symptoms. This suggests a novel neurotrophic-based mechanism of the drug effects of quetiapine on psychosis. This is the first report of VEGF perturbation in psychosis.
机译:目的。已经提出非典型抗精神病药通过脑源性神经营养因子(BDNF)赋予其作用。我们研究了喹硫平对未接受过药物的首发精神病患者血清BDNF和血管内皮生长因子(VEGF)的影响。从一项较大的研究中抽取的15名患者接受了喹硫平治疗12周。将血清BDNF和VEGF的基线水平与年龄和性别匹配的健康对照以及治疗后的水平进行比较。进行线性回归分析以确定BDNF和VEGF水平与基线和第12周时结局指标的关系。与基线相比,第12周的平均血清BDNF水平显着更高,并且与简短精神病评定量表(BPRS)和一般精神病理学评分降低有关。血清VEGF水平的变化也与BPRS分数的降低,PANNS阳性症状分数的显着改善显着相关,并且与BDNF水平的变化呈正相关。我们的发现表明,BDNF和VEGF是衡量精神病症状改善的潜在生物标志物。这表明喹硫平对精神病的药物作用基于神经营养的新机制。这是精神病中VEGF摄动的第一个报道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号